Thrombosis prevention after percutaneous coronary intervention in patient at high gastric ulcer risk

This clinical indication refers to the prevention of acute and subacute ischemic complications—primarily stent thrombosis and recurrent myocardial infarction—in cardiovascular patients undergoing percutaneous coronary intervention (PCI) who also present with an elevated risk of mucosal injury, peptic ulceration, or upper gastrointestinal bleeding Following coronary stent placement, mechanical vascular injury and thrombogenic foreign surfaces provoke platelet activation and fibrin deposition, nec...

This clinical indication refers to the prevention of acute and subacute ischemic complications—primarily stent thrombosis and recurrent myocardial infarction—in cardiovascular patients undergoing percutaneous coronary intervention (PCI) who also present with an elevated risk of mucosal injury, peptic ulceration, or upper gastrointestinal bleeding Following coronary stent placement, mechanical vascular injury and thrombogenic foreign surfaces provoke platelet activation and fibrin deposition, nec...

This clinical indication refers to the prevention of acute and subacute ischemic complications—primarily stent thrombosis and recurrent myocardial infarction—in cardiovascular patients undergoing percutaneous coronary intervention (PCI) who also present with an elevated risk of mucosal injury, peptic ulceration, or upper gastrointestinal bleeding

Following coronary stent placement, mechanical vascular injury and thrombogenic foreign surfaces provoke platelet activation and fibrin deposition, necessitating antithrombotic regimens

However, systemic platelet inhibition simultaneously impairs hemostasis and exacerbates preexisting mucosal erosions or ulcer diatheses within the gastrointestinal tract This defining clinical scenario represents a narrow therapeutic window characterized by competing high ischemic and high hemorrhagic risks, requiring tailored antithrombotic strategies coupled with gastroprotective co-therapy to maintain vascular patency while preventing major gastric hemorrhage

However, systemic platelet inhibition simultaneously impairs hemostasis and exacerbates preexisting mucosal erosions or ulcer diatheses within the gastrointestinal tract

This defining clinical scenario represents a narrow therapeutic window characterized by competing high ischemic and high hemorrhagic risks, requiring tailored antithrombotic strategies coupled with gastroprotective co-therapy to maintain vascular patency while preventing major gastric hemorrhage